Skip to main content

Advertisement

SpringerLink
Log in

Deoxyribonuclease activity of polyclonal IgGs: a putative serological marker in patients with spondyloarthritides

  • Diagnosis of Autoimmunity
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Antibodies executing catalytic activity are referred to as antibody enzymes or short “abzymes” and may have diagnostic relevance. Abzymes with deoxyribonuclease (DNase) activity have been demonstrated in patients with autoimmune and infectious diseases. Despite several reports on the occurrence of DNase abzymes in systemic autoimmune rheumatic diseases, conclusive data about DNase activity of antibodies in patients with spondyloarthritides (SpAs) are lacking. In recent cross-sectional studies evaluating levels of IgG DNase activity in patients with psoriatic arthritis (PsA), reactive arthritis (ReA), and ankylosing spondylitis (AS), DNase activity of IgG has been assessed by the rivanol clot method and confirmed by agarose gel electrophoresis. Remarkably, levels of IgG DNase activity were significantly higher in sera of SpA patients than those in control subjects. In patients with PsA, ReA, and AS, a positive correlation of DNase IgG activity with synovitis, disease activity, and stage of spondylitis was observed, respectively. Given the involvement of autoimmune reactions in cytolysis and connective tissue degradation in PsA, ReA, and to a lesser extent in AS, abzymes might have an impact on the pathophysiology of SpAs. Detection of IgG DNase activity in patients suffering from SpA represents an exciting new research field and may assist in the differential diagnosis of SpA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

Abzyme:

Antibody enzymes

AD:

Alzheimer’s disease

AS:

Ankylosing spondylitis

BASDAI:

Bath Ankylosing Spondylitis Disease Activity Index

BASFI:

Bath Ankylosing Spondylitis Functional Index

BASRI:

Bath Ankylosing Spondylitis Radiology Index

CRP:

C-reactive protein

DMARDs:

Disease-modifying antirheumatic drugs

DNA:

Deoxyribonucleic acid

DNase:

Deoxyribonuclease

ESSG:

European Spondyloarthropathy Study Group

HT:

Hashimoto’s thyroiditis

MASES:

Maastricht Ankylosing Spondylitis Enthesitis Score

MBP:

Myelin basic protein

NSAID:

Nonsteroidal anti-inflammatory drugs

PsA:

Psoriatic arthritis

RA:

Rheumatoid arthritis

ReA:

Reactive arthritis

RNA:

Ribonucleic acid

SDS-PAGE:

Sodium dodecyl sulfate–polyacrylamide gel electrophoresis

SLE:

Systemic lupus erythematosus

SpA/SpAs:

Spondyloarthritis/spondyloarthritides

References

  1. Nevinsky GA, Buneva VN. Catalytic antibodies in healthy humans and patients with autoimmune and viral diseases. J Cell Mol Med. 2003;7:265–76.

    Article  PubMed  CAS  Google Scholar 

  2. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov AG. DNA hydrolyzing autoantibodies. Science. 1992;256:665–7.

    Article  PubMed  CAS  Google Scholar 

  3. Wootla B, Lacroix-Desmazes S, Warrington AE, Bieber AJ, Kaveri SV, Rodriguez M. Autoantibodies with enzymatic properties in human autoimmune diseases. J Autoimmun. 2011;37:144–50.

    Article  PubMed  CAS  Google Scholar 

  4. Pavlovic M, Kats A, Cavallo M, Chen R, Hartmann JX, Shoenfeld Y. Pathogenic and epiphenomenal anti-DNA antibodies in SLE. Autoimmune Dis. 2011;2011:462841.

    Google Scholar 

  5. Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Paul S. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev. 2008;7:391–7.

    Article  PubMed  CAS  Google Scholar 

  6. Kozyr AV, Kolesnikov AV, Aleksandrova ES, Sashchenko LP, Gnuchev NV, Favorov PV, Kotelnikov MA, Iakhnina EI, Astsaturov IA, Prokaeva TB, Alekberova ZS, Suchkov SV, Gabibov AG. Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases. Appl Biochem Biotechnol. 1998;75:45–61.

    Article  PubMed  CAS  Google Scholar 

  7. Baranovsky AG, Matushin VG, Vlassov AV, Zabara VG, Naumov VA, Giege R, Buneva VN, Nevinsky GA. DNA- and RNA-hydrolyzing antibodies from the blood of patients with various forms of viral hepatitis. Biochemistry (Mosc). 1997;62:1358–66.

    PubMed  CAS  Google Scholar 

  8. Baranovskii AG, Kanyshkova TG, Mogelnitskii AS, Naumov VA, Buneva VN, Gusev EI, Boiko AN, Zargarova TA, Favorova OO, Nevinsky GA. Polyclonal antibodies from blood and cerebrospinal fluid of patients with multiple sclerosis effectively hydrolyze DNA and RNA. Biochemistry (Mosc). 1998;63:1239–48.

    PubMed  CAS  Google Scholar 

  9. Kalaga R, Li L, O’Dell JR, Paul S. Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis. J Immunol. 1995;155:2695–702.

    PubMed  CAS  Google Scholar 

  10. Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S. Catalytic antibodies to HIV: physiological role and potential clinical utility. Autoimmun Rev. 2008;7:473–9.

    Article  PubMed  CAS  Google Scholar 

  11. Gabibov AG, Ponomarenko NA, Tretyak EB, Paltsev MA, Suchkov SV. Catalytic autoantibodies in clinical autoimmunity and modern medicine. Autoimmun Rev. 2006;5:324–30.

    Article  PubMed  CAS  Google Scholar 

  12. Nevinsky GA, Kanyshkova TG, Buneva VN. Natural catalytic antibodies (abzymes) in normalcy and pathology. Biochemistry (Mosc). 2000;65:1245–55.

    PubMed  CAS  Google Scholar 

  13. Ponomarenko NA, Durova OM, Vorobiev II, Belogurov AA Jr, Kurkova IN, Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM, Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC III, Thomas D, Friboulet A, Gabibov AG. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci USA. 2006;103:281–6.

    Article  PubMed  CAS  Google Scholar 

  14. Breusov AA, Gal’vita AV, Benzo ES, Baranovskii AG, Prints AV, Naumov VA, Buneva VN, Nevinsky GA. Comparison of the level of DNA-hydrolyzing polyclonal IgG antibodies in sera of patients with Hashimoto’s thyroiditis and nontoxic nodal goiter. Russ J Immunol. 2001;6:17–28.

    PubMed  CAS  Google Scholar 

  15. Andrievskaya OA, Buneva VN, Baranovskii AG, Gal’vita AV, Benzo ES, Naumov VA, Nevinsky GA. Catalytic diversity of polyclonal RNA-hydrolyzing IgG antibodies from the sera of patients with systemic lupus erythematosus. Immunol Lett. 2002;81:191–8.

    Article  PubMed  CAS  Google Scholar 

  16. Bayry J, Lacroix-Desmazes S, Pashov A, Stahl D, Hoebeke J, Kazatchkine MD, Kaveri SV. Autoantibodies to factor VIII with catalytic activity. Autoimmun Rev. 2003;2:30–5.

    Article  PubMed  CAS  Google Scholar 

  17. Kundzer EV, Generalov II, Volkova MV. DNAse serum and catalytic IgG activity in patients with spondyloarthropathies. Ann Rheum Dis. 2011;70(suppl 13):336.

    Google Scholar 

  18. Kundzer EV, Volkova MV. DNAse serum and IgG activity in patients with axial and peripheral spondyloarthropathies. Ann Rheum Dis. 2012;71(suppl 13):557.

    Google Scholar 

  19. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov AG. Interaction of catalytically active antibodies with DNA. Dokl Akad Nauk SSSR. 1991;319:1504–7.

    PubMed  CAS  Google Scholar 

  20. Shuster AM, Gololobov GV, Kvashuk OA, Gabibov AG. Dna-specific catalytic antibodies in human blood sera. Dokl Akad Nauk SSSR. 1991;318:1262–4.

    PubMed  CAS  Google Scholar 

  21. Parkhomenko TA, Odintsova ES, Buneva VN, Kunder EV, Zhyltsov IV, Senkovich SA, Generalov II, Nevinsky GA. DNA-hydrolysing activity of IgG antibodies from the sera of patients with diseases caused by different bacterial infections. J Cell Mol Med. 2009;13:2875–87.

    Article  PubMed  CAS  Google Scholar 

  22. Gololobov GV, Bogomolova AE, Iadav RP, Ermolaeva MV, Belostotskaia KM, Prokaeva TB, Shuster AM, Gabibov AG. Isolation and characteristics of catalytic antibodies to DNA in systemic lupus erythematosus. Biokhimiia. 1993;58:313–8.

    PubMed  CAS  Google Scholar 

  23. Gabibov AG, Gololobov GV, Makarevich OI, Schourov DV, Chernova EA, Yadav RP. DNA-hydrolyzing autoantibodies. Appl Biochem Biotechnol. 1994;47:293–302.

    Article  PubMed  CAS  Google Scholar 

  24. Khitrov AN, Romadanova NB, Ogneva EA, Naumova TE, Alekberova ZS, Vorob’ev II, Gabibov AG, Ponomarenko NA, Suchkov SV. DNA-abzymes in rheumatoid arthritis: pathogenetic and clinical significance. Ter Arkh. 2005;77:75–80.

    PubMed  CAS  Google Scholar 

  25. Buneva VN, Kudryavtseva AN, Gal’vita AV, Dubrovskaya VV, Khokhlova OV, Kalinina IA, Galenok VA, Nevinsky GA. Dynamics of antibody nuclease activity in blood of women during pregnancy and lactation. Biochemistry (Mosc). 2003;68:890–900.

    Article  PubMed  CAS  Google Scholar 

  26. Kanyshkova TG, Semenov DV, Khlimankov DY, Buneva VN, Nevinsky GA. DNA-hydrolyzing activity of the light chain of IgG antibodies from milk of healthy human mothers. FEBS Lett. 1997;416:23–6.

    Article  PubMed  CAS  Google Scholar 

  27. Li L, Paul S, Tyutyulkova S, Kazatchkine MD, Kaveri S. Catalytic activity of anti-thyroglobulin antibodies. J Immunol. 1995;154:3328–32.

    PubMed  CAS  Google Scholar 

  28. Vlassov A, Florentz C, Helm M, Naumov V, Buneva V, Nevinsky G, Giege R. Characterization and selectivity of catalytic antibodies from human serum with RNase activity. Nucleic Acids Res. 1998;26:5243–50.

    Article  PubMed  CAS  Google Scholar 

  29. Gabibov AG, Kozyr AV, Kolesnikov AV. Disease association and cytotoxic effects of DNA-hydrolyzing autoantibodies. Chem Immunol. 2000;77:130–56.

    Article  PubMed  CAS  Google Scholar 

  30. Gololobov GV, Mikhalap SV, Starov AV, Kolesnikov AF, Gabibov AG. DNA-protein complexes. Natural targets for DNA-hydrolyzing antibodies. Appl Biochem Biotechnol. 1994;47:305–14.

    Article  PubMed  CAS  Google Scholar 

  31. Kozyr AV, Kolesnikov AV, Zelenova NA, Sashchenko LP, Mikhalap SV, Bulina ME, Ignatova AN, Favorov PV, Gabibov AG. Autoantibodies to nuclear antigens: correlation between cytotoxicity and DNA-hydrolyzing activity. Appl Biochem Biotechnol. 2000;83:255–68.

    Article  PubMed  CAS  Google Scholar 

  32. Lee EJ, Jang EJ, Lee E, Yu J, Chung HY, Jang YJ. Cell-penetrating autoantibody induces caspase-mediated apoptosis through catalytic hydrolysis of DNA. Bioorg Med Chem. 2007;15:2016–23.

    Article  PubMed  CAS  Google Scholar 

  33. Belogurov AA, Kurkova IN, Misikov VK, Suchkov SV, Telegin GB, Alekhine AI, Goncharov NG, Knorre VD, Gabibov AG, Ponomarenko NA. Substrate specificity of catalytic autoantibodies in neurodegenerative processes. Dokl Biochem Biophys. 2007;413:61–4.

    Article  PubMed  CAS  Google Scholar 

  34. Ponomarenko NA, Durova OM, Vorobiev II, Belogurov AA, Telegin GB, Suchkov SV, Misikov VK, Morse HC III, Gabibov AG. Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol Lett. 2006;103:45–50.

    Article  PubMed  CAS  Google Scholar 

  35. Lacroix-Desmazes S, Wootla B, Dasgupta S, Delignat S, Bayry J, Reinbolt J, Hoebeke J, Saenko E, Kazatchkine MD, Friboulet A, Christophe O, Nagaraja V, Kaveri SV. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J Immunol. 2006;177:1355–63.

    PubMed  CAS  Google Scholar 

  36. Wootla B, Mahendra A, Dimitrov JD, Friboulet A, Borel-Derlon A, Rao DN, Uda T, Borg JY, Bayry J, Kaveri SV, Lacroix-Desmazes S. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. FEBS Lett. 2009;583:2565–72.

    Article  PubMed  CAS  Google Scholar 

  37. Wootla B, Rao DN, Friboulet A, Uda T, Lacroix-Desmazes S, Kaveri SV. Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies. Clin Rev Allergy Immunol. 2009;37:97–104.

    Article  PubMed  CAS  Google Scholar 

  38. Kolesnikov AV, Kozyr AV, Alexandrova ES, Koralewski F, Demin AV, Titov MI, Avalle B, Tramontano A, Paul S, Thomas D, Gabibov AG, Friboulet A. Enzyme mimicry by the antiidiotypic antibody approach. Proc Natl Acad Sci USA. 2000;97:13526–31.

    Article  PubMed  CAS  Google Scholar 

  39. Ehrenfeld M. Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev. 2010;9:A325–9.

    Article  PubMed  Google Scholar 

  40. Bowness P. HLA B27 in health and disease: a double-edged sword? Rheumatology (Oxford). 2002;41:857–68.

    Article  CAS  Google Scholar 

  41. Mathieu A, Paladini F, Vacca A, Cauli A, Fiorillo MT, Sorrentino R. The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. Autoimmun Rev. 2009;8:420–5.

    Article  PubMed  CAS  Google Scholar 

  42. Chatzikyriakidou A, Voulgari PV, Drosos AA. What is the role of HLA-B27 in spondyloarthropathies? Autoimmun Rev. 2011;10:464–8.

    Article  PubMed  CAS  Google Scholar 

  43. Hoffman IE, Demetter P, Peeters M, De VM, Mielants H, Veys EM, De KF. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis. 2003;62:455–9.

    Article  PubMed  CAS  Google Scholar 

  44. Mundwiler ML, Mei L, Landers CJ, Reveille JD, Targan S, Weisman MH. Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study. Arthr Res Ther. 2009;11:R177.

    Article  Google Scholar 

  45. Baerlecken N, Stummvoll GH, Rudwaleit M, Sieper J, Schmidt RE, Witte T. Autoantibodies against class II—associated invariant chain peptide (CLIP) in spondyloarthritis? 8th Autoimmune congress on Autoimmunity. 2012.

  46. De RL, Kruithof E, Van DN, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De KF. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum. 2003;48:1015–23.

    Article  Google Scholar 

  47. Johnson SR, Schentag CT, Gladman DD. Autoantibodies in biological agent naive patients with psoriatic arthritis. Ann Rheum Dis. 2005;64:770–2.

    Article  PubMed  CAS  Google Scholar 

  48. Calzavara-Pinton PG, Franceschini F, Manera C, Zane C, Prati E. Incidence of antiperinuclear factor in patients with psoriatic arthritis. Adv Exp Med Biol. 1999;455:215–20.

    Article  PubMed  CAS  Google Scholar 

  49. Conrad K, Ittenson A, Reinhold D, Fischer R, Roggenbuck D, Buttner T, Bosselmann HP, Steinbach J, Schossler W. High sensitive detection of double-stranded DNA autoantibodies by a modified Crithidia luciliae immunofluorescence test. Ann N Y Acad Sci. 2009;1173:180–5.

    Article  PubMed  CAS  Google Scholar 

  50. Roggenbuck D, Conrad K, Reinhold D. High sensitive detection of double-stranded DNA antibodies by a modified Crithidia luciliae immunofluorescence test may improve diagnosis of systemic lupus erythematosus. Clin Chim Acta. 2010;411:1837–8.

    Article  PubMed  CAS  Google Scholar 

  51. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum. 1991;34:1218–27.

    Article  PubMed  CAS  Google Scholar 

  52. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.

    Article  PubMed  Google Scholar 

  53. Braun J, Kingsley G, van der Heijde D, Sieper J. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3–6, 1999. J Rheumatol. 2000;27:2185–92.

    PubMed  CAS  Google Scholar 

  54. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.

    Article  PubMed  Google Scholar 

  55. van de Kerkhof PC. The Psoriasis Area and Severity Index and alternative approaches for the assessment of severity: persisting areas of confusion. Br J Dermatol. 1997;137:661–2.

    Article  PubMed  Google Scholar 

  56. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G, Salonen D. Radiological assessment in psoriatic arthritis. Br J Rheumatol. 1998;37:760–5.

    Article  PubMed  CAS  Google Scholar 

  57. MacKay K, Mack C, Brophy S, Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. 1998;41:2263–70.

    Article  PubMed  CAS  Google Scholar 

  58. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewe R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum. 2004;51:154–9.

    Article  PubMed  Google Scholar 

  59. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.

    PubMed  CAS  Google Scholar 

  60. Conrad K, Roggenbuck D, Reinhold D, Sack U. Autoantibody diagnostics in clinical practice. Autoimmun Rev. 2011;207–211.

  61. Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev. 2009;8:543–8.

    Article  PubMed  CAS  Google Scholar 

  62. Hiemann R, Buttner T, Krieger T, Roggenbuck D, Sack U, Conrad K. Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells. Autoimmun Rev. 2009;9:17–22.

    Article  PubMed  CAS  Google Scholar 

  63. Grossmann K, Roggenbuck D, Schroder C, Conrad K, Schierack P, Sack U. Multiplex assessment of non-organ-specific autoantibodies with a novel microbead-based immunoassay. Cytom A. 2011;79:118–25.

    Article  Google Scholar 

  64. Rodiger S, Schierack P, Bohm A, Nitschke J, Berger I, Frommel U, Schmidt C, Ruhland M, Schimke I, Roggenbuck D, Lehmann W, Schroder C. A highly versatile microscope imaging technology platform for the multiplex real-time detection of biomolecules and autoimmune antibodies. Adv Biochem Eng Biotechnol. 2012 (in press).

  65. Willitzki A, Hiemann R, Peters V, Sack U, Schierack P, Rodiger S, Anderer U, Bogdanos DP, Reinhold D, Roggenbuck D. New platform technology for comprehensive serological diagnostics of autoimmune disease. Clin Dev Immunol. 2012;2012:284740.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

A.K. and M.V. were supported by the Belorussian Republican Foundation and Fundamental Research (BRFFR (04-04-81017): the Belorussian State Scientific Technical Program “Treatment and Diagnostic Technologies” (01.12.2006–2008) and the Russian Foundation of Basic Research (RFBR). We would like to thank Samantha Goddard for excellent language assistance.

Conflict of interest

Dirk Roggenbuck is a shareholder of GA Generic Assays GmbH and Medipan GmbH. The remaining authors declare that they have no competing financial interests.

Author information

Authors and Affiliations

  1. Belarusian Medical Academy of Post-graduate Education, 220013, Minsk, Belarus

    Alena V. Kundzer

  2. Vitebsk State Medical University, 210023, Vitebsk, Belarus

    Margarita V. Volkova & I. Generalov

  3. Transplantation Immunology and Mucosal Biology, King’s College London School of Medicine at King’s College Hospital, Bessemer Road, London, SE5 9RJ, UK

    Dimitrios P. Bogdanos

  4. Siberian Division, Institute of Chemical Biology and Fundamental Medicine, Russian Academy of Science, Novosibirsk, 630090, Russia

    Georgy A. Nevinsky

  5. GA Generic Assays GmbH, 15827, Dahlewitz, Berlin, Germany

    Dirk Roggenbuck

  6. Faculty of Natural Sciences, University of Applied Sciences, Großenhainer Str. 57, 01968, Senftenberg, Germany

    Stefan Rödiger, Peter Schierack & Dirk Roggenbuck

Authors
  1. Alena V. Kundzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margarita V. Volkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitrios P. Bogdanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefan Rödiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Schierack
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. Generalov
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Georgy A. Nevinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dirk Roggenbuck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Roggenbuck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kundzer, A.V., Volkova, M.V., Bogdanos, D.P. et al. Deoxyribonuclease activity of polyclonal IgGs: a putative serological marker in patients with spondyloarthritides. Immunol Res 56, 457–464 (2013). https://doi.org/10.1007/s12026-013-8424-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-013-8424-9

Keywords

Search

Navigation